Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 231,834
  • Shares Outstanding, K 162,122
  • Annual Sales, $ 650 K
  • Annual Income, $ -24,420 K
  • 60-Month Beta N/A
  • Price/Sales 349.44
  • Price/Cash Flow N/A
  • Price/Book 2.99
Trade CYBN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/15/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-6770 Blank Checks

    Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.09
  • Number of Estimates 4
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2900 +9.30%
on 11/26/21
2.3550 -40.13%
on 11/05/21
-0.4600 (-25.00%)
since 11/02/21
3-Month
1.2900 +9.30%
on 11/26/21
2.7500 -48.73%
on 09/07/21
-1.0900 (-43.82%)
since 09/02/21
52-Week
0.7223 +95.21%
on 12/03/20
3.3800 -58.28%
on 08/02/21
+0.7200 (+101.43%)
since 12/02/20

Most Recent Stories

More News
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting in the upcoming Stifel GMP second annual Future of Healthcare...

CYBN : 1.3900 (-2.80%)
Study Finds That Holiday Season May Worsen Mental Health

A  recent study  conducted by the National Alliance of Mental Illness has found that symptoms of mental illness may worsen during the holiday season. Participants who were part of the study who  suffered...

CYBN : 1.3900 (-2.80%)
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that...

CYBN.NE : 1.820 (+0.55%)
CYBN : 1.3900 (-2.80%)
Psychedelics Firms Race to Shorten Therapeutic Trips’ Duration

Research on psychedelics has grown tremendously these past few years, as more about potential health benefits are discovered. For instance, substances such as psilocybin and MDMA have shown potential...

CYBN : 1.3900 (-2.80%)
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received authorization from the U.S. Food and Drug Administration (“FDA”)...

CYBN : 1.3900 (-2.80%)
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that the...

CYBN.NE : 1.820 (+0.55%)
CYBN : 1.3900 (-2.80%)
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that...

CYBN.NE : 1.820 (+0.55%)
CYBN : 1.3900 (-2.80%)
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has reported that its wholly controlled subsidiary, Adelia Therapeutics Inc.,...

CYBN : 1.3900 (-2.80%)
Psilocybin Mushroom Measure May Make Pennsylvania New Psychedelic Research Hub

The state of Pennsylvania may become the new psychedelic research hub in the United States if a measure that was introduced in the state’s House of Representatives in October is approved. The measure,...

CYBN : 1.3900 (-2.80%)
3 Psychedelics Stocks Wall Street Predicts Will Soar

Psychedelic substances like MDMA and psilocybin show great potential in treating patients with neurological or psychiatric problems. Therefore, drug development companies are showing an increasing interest...

MNMD : 1.8850 (-1.31%)
CYBN : 1.3900 (-2.80%)
FTRP : 3.41 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 1.6780
2nd Resistance Point 1.6090
1st Resistance Point 1.5195
Last Price 1.3900
1st Support Level 1.3610
2nd Support Level 1.2920
3rd Support Level 1.2025

See More

52-Week High 3.3800
Fibonacci 61.8% 2.3648
Fibonacci 50% 2.0512
Fibonacci 38.2% 1.7375
Last Price 1.3900
52-Week Low 0.7223

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar